Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

NCT04394858 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04394858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04394858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 17, 2021
Completion date
March 1, 2028
Enrollment
46 (estimated)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

advanced adrenal gland pheochromocytoma, advanced paraganglioma, metastatic adrenal gland pheochromocytoma, metastatic paraganglioma, stage iii adrenal gland pheochromocytoma and sympathetic paraganglioma ajcc v8, stage iv adrenal gland pheochromocytoma and sympathetic paraganglioma ajcc v8, unresectable adrenal gland pheochromocytoma, unresectable paraganglioma